This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Abraham, B.K. and Adithan, C. (2001). Genetic polymorphism of CY2D6. Indian J. Pharmacol., 33, 147–169.
Adedoyin, A., Frye, R.F., Mauro, K. et al. (1998). Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drugs cocktail. Br. J. Clin. Pharmacol., 46, 215–219.
Ahmed, A., Bararia, D., Vinayak, S. et al. (2004). Plasmodium falciparum isolates in India exhibits a progressive increase in mutations associated with sulfadoxine-pyrimethamine resistance. Antimicrob. Agents Chemother., 48, 879–889.
Alonso, P.L., Sacarlal, J., Aponte, J.J. et al. (2004). Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: Randomized controlled trial. Lancet, 364, 1411–1420.
Anderson, T.J. (2004). Mapping drug-resistance genes in Plasmodium falciparum by genome-wide association. Curr. Drug Targets Infect. Disord., 4, 65–78.
Anderson, T.J., Nair, S., Jacobzone, C. et al. (2003). Molecular assessment of drug resistance in Plasmodium falciparum from Bahr El Gazal province, Sudan. Trop. Med. Int. Health, 8, 1068–1073.
Angus, B.J., Thaiaporn, I., Chanthapadith, K. et al. (2002). Oral artesunate dose-response relationship in acute falciparum malaria. Antimicrob. Agents Chemother., 46, 778–782.
Baird, J.K., Basri, H., Purnomo et al. (1991). Resistance to chloroquine by Plasmodium vivax in Irian Jaya, Indonesia. Am. J. Trop. Med. Hyg., 44, 547–552.
Baird, J.K., Sustriayu Nalim, M.F., Basri, H. et al. (1996). Survey of resistance to chloroquine by Plasmodium vivax in Indonesia. Trans. R. Soc. Trop. Med. Hyg., 90, 409–411.
Balint, G.A. (2001). Artemisinin and its derivatives: An important new class of antimalarial agents. Pharmaco. Ther., 90, 261–265.
Ball, S. and Borman, N. (1997). Pharmacogenetics and drug metabolism. Nat. Biotechnol., 15, 925–926.
Bangchang, K.N., Karbwang, J., and Back, D.J. (1992a). Mefloquine metabolism by human liver microsomes. Effect of other antimalarial drugs. Biochem. Pharmacol., 43, 1957–1961.
Bangchang, K.N., Karbwang, J., and Back, D.J. (1992b). Primaquine metabolism by human liver microsomes: effect of other antimalarial drugs. Biochem. Pharmacol., 44, 587–590.
Bapiro, T.E., Egnell, A.C., Hasler, J.A. et al. (2001). Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab. Dispos., 29, 30–35.
Bapiro, T.E., Andersson, T.B., Otter, C. et al. (2002a). Cytochrome P450 1A1/2 induction by antiparasitic drugs: Dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur. J. Clin. Pharmacol., 58, 537–542.
Bapiro, T.E., Hasler, J.A., Ridderstrom, M. et al. (2002b). The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations. Biochem. Pharmacol., 64, 1387–1398.
Basco, L.K., Same-Ekobo, A., Ngane, V.F. et al. (2002). Therapeutic efficacy of sulfadoxine-pyrimethamine, amodiaquine and the sulfadoxine-pyrimethamine-amodiaquine combination against uncomplicated Plasmodium falciparum malaria in young children in Cameroon. Bull. World Health Organ., 80, 538–545.
Baune, B., Flinois, J.P., Furlan, V. et al. (1999). Halofantrine metabolism in microsomes in man: major role of CYP 3A4 and CYP 3A5. J. Pharm. Pharmacol., 51, 419–426.
Baune, B., Furlan, V., Taburet, A.M. et al. (1999). Effect of selected antimalarial drugs and inhibitors of cytochrome P-450 3A4 on halofantrine metabolism by human liver microsomes. Drug Metab. Dispos., 27, 565–568.
Beaulieu, M., Levesque, E., Tchernof, A. et al. (1997). Chromosomal localization, structure, and regulation of the UGT2B17 gene, encoding a C19 steroid metabolizing enzyme. DNA Cell. Biol., 16, 1143–1154.
Bennett, T.N., Kosar, A.D., Ursos, L.M. et al. (2004). Drug resistance-associated pfCRT mutations confer decreased Plasmodium falciparum digestive vacuolar pH. Mol. Biochem. Parasitol., 133, 99–114.
Birkett, D.J., Rees, D., Andersson, T. et al. (1994). In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase. Br. J. Clin. Pharmacol., 37, 413–420.
Bloland, P.B. (2001). Drug resistance in malaria. WHO/CDS/CSR/DRS/2001. 4, 1–27.
Bloland, P.B., Ettling, M., and Meek, S. (2000). Combination therapy for malaria in Africa: hype or hope? Bull. World Health Organ., 78, 1378–1388.
Bock, K.W. (2003). Vertebrate UDP-glucuronosyltransferases: Functional and evolutionary aspects. Biochem. Pharmacol., 66, 691–696.
Bolaji, O.O., Sadare, I.O., Babalola, C.P. et al. (2002). Polymorphic oxidative metabolism of proguanil in a Nigerian population. Eur. J. Clin. Pharmacol., 58, 543–545.
Brabin, B.J., Ginny, M., Sapau, J. et al. (1990). Consequences of maternal anaemia on outcome of pregnancy in a malaria endemic area in Papua New Guinea. Ann. Trop. Med. Parasitol., 84, 11–24.
Brega, S., Meslin, B., de Monbrison, F. et al. (2005). Identification of the Plasmodium vivax mdrlike gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity. J. Infect. Dis., 191, 272–277.
Brockman, A., Price, R.N., van Vugt, M. et al. (2000). Plasmodium falciparum antimalarial drug susceptibility on the northwestern border of Thailand during five years of extensive use of artesunate-mefloquine. Trans. R. Soc. Trop. Med. Hyg., 94, 537–544.
Brooks, D.R., Wang, P., Read, M. et al. (1994). Sequence variation of the hydroxymethyldihydropterin pyrophosphokinase: Dihydropteroate synthase gene in lines of the human malaria parasite, Plasmodium falciparum, with differing resistance to sulfadoxine. Eur. J. Biochem., 224, 397–405.
Brossi, A., Venugopalan, B., Dominguez Gerpe, L. et al. (1988). Arteether, a new antimalarial drug: synthesis and antimalarial properties. J. Med. Chem., 31, 645–650.
Burchell, B. (2003). Genetic variation of human UDP-glucuronosyltransferase: Implications in disease and drug glucuronidation. Am. J. Pharmacogenomics, 3, 37–52.
Bustos, M.D., Gay, F., and Diquet, B. (1994). In-vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives. Bull. World Health Organ., 72, 729–735.
Bwijo, B., Kaneko, A., Takechi, M. et al. (2003). High prevalence of quintuple mutant dhps/dhfr genes in Plasmodium falciparum infections seven years after introduction of sulfadoxine and pyrimethamine as first line treatment in Malawi. Acta. Trop., 85, 363–373.
Bzik, D.J., Li, W.B., Horii, T. et al. (1987). Molecular cloning and sequence analysis of the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene. Proc. Natl. Acad. Sci. USA, 84, 8360–8364.
Caraco, Y. (1998). Genetic determinants of drug responsiveness and drug interactions. Ther. Drug Monit., 20, 517–524.
Carlton, J.M., Fidock, D.A., Djimde, A. et al. (2001). Conservation of a novel vacuolar transporter in Plasmodium species and its central role in chloroquine resistance of Plasmodium falciparum. Curr. Opin. Microbiol., 4, 415–420.
Cerutti, C. Jr., Durlacher, R.R., de Alencar, F.E. et al. (1999). In vivo efficacy of mefloquine for the treatment of Falciparum malaria in Brazil. J. Infect. Dis., 180, 2077–2080.
Chen, G.X., Mueller, C., Wendlinger, M. et al. (1987). Kinetic and molecular properties of the dihydrofolate reductase from pyrimethamine-sensitive and pyrimethamine-resistant clones of the human malaria parasite Plasmodium falciparum. Mol. Pharmacol., 31, 430–437.
Chen, N., Russell, B., Fowler, E. et al. (2002). Levels of chloroquine resistance in Plasmodium falciparum are determined by loci other than pfcrt and pfmdr1. J. Infect. Dis., 185, 405–407.
Chotivanich, K., Udomsangpetch, R., Chierakul, W. et al. (2004). In vitro efficacy of antimalarial drugs against Plasmodium vivax on the western border of Thailand. Am. J. Trop. Med. Hyg., 70, 395–397.
Collins, W.E. and Jeffery, G.M. (1996). Primaquine resistance in Plasmodium vivax. Am. J. Trop. Med. Hyg., 55, 243–249.
Collins, W.E., Jeffery, G.M., and Roberts, J.M. (2003). A retrospective examination of anemia during infection of humans with Plasmodium vivax. Am. J. Trop. Med. Hyg., 68, 410–412.
Contreras, C.E., Cortese, J.F., Caraballo, A. et al. (2002). Genetics of drug-resistant Plasmodium falciparum malaria in the Venezuelan state of Bolivar. Am. J. Trop. Med. Hyg., 67, 400–405.
Cooper, R.A., Ferdig, M.T., Su, X.Z. et al. (2002). Alternative mutations at position 76 of the vacuolar transmembrane protein PfCRT are associated with chloroquine resistance and unique stereospecific quinine and quinidine responses in Plasmodium falciparum. Mol. Pharmacol., 61, 35–42.
Cortese, J.F., Caraballo, A., Contreras, C.E. et al. (2002). Origin and dissemination of Plasmodium falciparum drug resistance mutations in South America. J. Infect. Dis., 186, 999–1006.
Cowman, A.F., Galatis, D., and Thompson, J.K. (1994). Selection for mefloquine resistance in Plasmodium falciparum is linked to amplification of the pfmdr1 gene and cross-resistance to halofantrine and quinine. Proc. Natl. Acad. Sci. USA, 91, 1143–1147.
Cowman, A.F., Karcz, S., Galatis, D. et al. (1991). A P-glycoprotein homologue of Plasmodium falciparum is localized on the digestive vacuole. J. Cell Biol., 113, 1033–1042.
Cowman, A.F., Morry, M.J., Biggs, B.A. et al. (1988). Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA, 85, 9109–9113.
Cox-Singh, J., Lu, H.Y., Davis, T.M. et al. (2003). Application of a multifaceted approach for the assessment of treatment response in falciparum malaria: A study from Malaysian Borneo. Int. J. Parasitol., 33, 1545–1552.
De Morais, S.M., Wilkinson, G.R., Blaisdell, J. et al. (1994). Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol., 46, 594–598.
de Pecoulas, P.E., Basco, L.K., Tahar, R. et al. (1998a). Analysis of the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene sequence. Gene, 211, 177–185.
de Pecoulas, P.E., Tahar, R., Ouatas, T. et al. (1998b). Sequence variations in the Plasmodium vivax dihydrofolate reductase-thymidylate synthase gene and their relationship with pyrimethamine resistance. Mol. Biochem. Parasitol., 92, 265–273.
de Vries, P.J. and Dien, T.K. (1996). Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs, 52, 818–836.
Demar, M. and Carme, B. (2004). Plasmodium falciparum in vivo resistance to quinine: Description of two RIII responses in French Guiana. Am. J. Trop. Med. Hyg., 70, 125–127.
Desowitz, R.S. and Spark, R.A. (1987). Malaria in the Maprik area of the Sepik region, Papua New Guinea: 1957–1984. Trans. R. Soc. Trop. Med. Hyg., 81, 175–176.
Destenaves, B. and Thomas, F. (2000). New advances in pharmacogenomics. Curr. Opin. Chem. Biol., 4, 440–444.
Dieckmann, A. and Jung, A. (1986). Mechanisms of sulfadoxine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol., 19, 143–147.
Dien, T.K., de Vries, P.J., Khanh, N.X. et al. (1997). Effect of food intake on pharmacokinetics of oral artemisinin in healthy Vietnamese subjects. Antimicrob. Agents Chemother., 41, 1069–1072.
Djimde, A.A., Doumbo, O.K., Traore, O. et al. (2003). Clearance of drug-resistant parasites as a model for protective immunity in Plasmodium falciparum malaria. Am. J. Trop. Med. Hyg., 69, 558–563.
Dua, V.K., Gupta, N.C., Kar, P.K. et al. (2000). Chloroquine and desethylchloroquine concentrations in blood cells and plasma from Indian patients infected with sensitive or resistant Plasmodium falciparum. Ann. Trop. Med. Parasitol., 94, 565–570.
Dua, V.K., Kar, P.K., and Sharma, V.P. (1996). Chloroquine resistant Plasmodium vivax malaria in India. Trop. Med. Int. Health, 1, 816–819.
Ducharme, J. and Farinotti, R. (1996). Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin. Pharmacokinet., 31 257–274.
Duraisingh, M.T., Roper, C., Walliker, D. et al. (2000). Increased sensitivity to the antimalarials mefloquine and artemisinin is conferred by mutations in the pfmdr1 gene of Plasmodium falciparum. Mol. Microbiol., 36, 955–961.
Durand, R., Jafari, S., Vauzelle, J. et al. (2001). Analysis of pfcrt point mutations and chloroquine susceptibility in isolates of Plasmodium falciparum. Mol. Biochem. Parasitol., 114, 95–102.
Edstein, M.D., Yeo, A.E., Kyle, D.E. et al. (1996). Proguanil polymorphism does not affect the antimalarial activity of proguanil combined with atovaquone in vitro. Trans. R. Soc. Trop. Med. Hyg., 90, 418–421.
Evans, W.E. and Relling, M.V. (1999). Pharmacogenomics: Translating functional genomics into rational therapeutics. Science, 286, 487–491.
Farnert, A., Lindberg, J., Gil, P. et al. (2003). Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports. BMJ., 326, 628–629.
Faye, F.B., Spiegel, A., Tall, A. et al. (2002). Diagnostic criteria and risk factors for Plasmodium ovale malaria. J. Infect. Dis., 186, 690–695.
Ferdig, M.T., Cooper, R.A., Mu, J., et al. (2004). Dissecting the loci of low-level quinine resistance in malaria parasites. Mol. Microbiol., 52, 985–997.
Fidock, D.A., Nomura, T., Talley, A.K. et al. (2000). Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol, Cell, 6, 861–871.
Fivelman, Q.L., Butcher, G.A., Adagu, I.S. et al. (2002). Malarone treatment failure and in vitro confirmation of resistance of Plasmodium falciparum isolate from Lagos, Nigeria. Malar. J., 1, 1.
Fontaine, F., de Sousa, G., Burcham, P.C. et al. (2000). Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes. Life Sci., 66, 2193–2212.
Foote, S.J., Galatis, D., and Cowman, A.F. (1990). Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA, 87, 3014–3017.
Foote, S.J., Kyle, D.E., Martin, R.K. et al. (1990). Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Nature, 345, 255–258.
Garavelli, P.L. and Corti, E. (1992). Chloroquine resistance in Plasmodium vivax: The first case in Brazil. Trans. R. Soc. Trop. Med. Hyg., 86, 128.
Gay, F., Ciceron, L., Litaudon, M. et al. (1994). In-vitro resistance of Plasmodium falciparum to qinghaosu derivatives in west Africa. Lancet, 343, 850–851.
Giao, P.T. and de Vries, P.J. (2001). Pharmacokinetic interactions of antimalarial agents. Clin. Pharmacokinet., 40, 343–373.
Giao, P.T., Binh, T.Q., Kager, P.A. et al. (2001). Artemisinin for treatment of uncomplicated falciparum malaria: Is there a place for monotherapy? Am. J. Trop. Med. Hyg., 65, 690–695.
Giao, P.T., de Vries, P.J., Hung le, Q. et al. (2004). CV8, a new combination of dihydroartemisinin, piperaquine, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam. Trop. Med. Int. Health, 9, 209–216.
Goldenberg, R.L. and Thompson, C. (2003). The infectious origins of stillbirth. Am. J. Obstet. Gynecol., 189, 861–873.
Goldstein, J.A. (2001). Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br. J. Clin. Pharmacol., 52, 349–355.
Gong, Q.H., Cho, J.W., Huang, T. et al. (2001). Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics, 11, 357–368.
Gonzalez, I.J., Varela, R.E., Murillo, C. et al. (2003). Polymorphisms in cg2 and pfcrt genes and resistance to chloroquine and other antimalarials in vitro in Plasmodium falciparum isolates from Colombia. Trans. R. Soc. Trop. Med. Hyg., 97, 318–324.
Goodman & Gilman’s The Pharmacological Basis of Therapeutics (2001). J.G. Hardman, L.E. Limbird, and A.G. Gilman (eds), 10th ed. McGraw-Hill.
Grace, J.M., Aguilar, A.J., Trotman, K.M. et al. (1998). Metabolism of beta-arteether to dihydroqinghaosu by human liver microsomes and recombinant cytochrome P450. Drug Metab. Dispos., 26, 313–317.
Grace, J.M., Skanchy, D.J., and Aguilar, A.J. (1999). Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A. Xenobiotica, 29, 703–717.
Griese, E.U., Ilett, K.F., Kitteringham, N.R. et al. (2001). Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19, and 2E1 in aborigines from western Australia. Pharmacogenetics, 11, 69–76.
Guengerich, F.P. (2003). Cytochromes P450, drugs, and diseases. Mol. Interv., 3, 194–204.
Guillemette, C. (2003). Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J., 3, 136–158.
Gupta, S., Thapar, M.M., Mariga, S.T. et al. (2002a). Plasmodium falciparum: in vitro interactions of artemisinin with amodiaquine, pyronaridine, and chloroquine. Exp. Parasitol., 100, 28–35.
Gupta, S., Thapar, M.M., Wernsdorfer, W.H. et al. (2002b). In vitro interactions of artemisinin with atovaquone, quinine, and mefloquine against Plasmodium falciparum. Antimicrob. Agents Chemother., 46, 1510–1515.
Guyatt, H.L. and Snow, R.W. (2001). Malaria in pregnancy as an indirect cause of infant mortality in sub-Saharan Africa. Trans. R. Soc. Trop. Med. Hyg., 95, 569–576.
Halpaap, B., Ndjave, M., Paris, M. et al. (1998). Plasma levels of artesunate and dihydroartemisinin in children with Plasmodium falciparum malaria in Gabon after administration of 50-mg artesunate suppositories. Am. J. Trop. Med. Hyg., 58, 365–368.
Hartl, D.L. (2004). The origin of malaria: mixed messages from genetic diversity. Nat. Rev. Microbiol., 2, 15–22.
Hastings, I.M., Watkins, W.M., and White, N.J. (2002). The evolution of drug-resistant malaria: The role of drug elimination half-life. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 357, 505–519.
Hastings, M.D., Porter, K.M., Maguire, J.D. et al. (2004). Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. J. Infect. Dis., 189, 744–750.
Hay, S.I., Guerra, C.A., Tatem, A.J. et al. (2004). The global distribution and population at risk of malaria: past, present, and future. Lancet Infect. Dis., 4, 327–336.
Hayton, K. and Su, X.Z. (2004). Genetic and biochemical aspects of drug resistance in malaria parasites. Curr. Drug Targets Infect. Disord., 4, 1–10.
Hellgren, U., Alvan, G., and Jerling, M. (1993). On the question of interindividual variations in chloroquine concentrations. Eur. J. Clin. Pharmacol., 45, 383–385.
Hellgren, U., Ericsson, O., Kihamia, C.M. et al. (1994). Malaria parasites and chloroquine concentrations in Tanzanian schoolchildren. Trop. Med. Parasitol., 45, 293–297.
Hellgren, U., Kihamia, C.M., Mahikwano, L.F. et al. (1989). Response of Plasmodium falciparum to chloroquine treatment: Relation to whole blood concentrations of chloroquine and desethylchloroquine. Bull. World Health Organ., 67, 197–202.
Helsby, N.A., Edwards, G., Breckenridge, A.M. et al. (1993). The multiple dose pharmacokinetics of proguanil. Br. J. Clin. Pharmacol., 35, 653–656.
Hoshen, M.B., Na-Bangchang, K., Stein, W.D., et al. (2000). Mathematical modeling of the chemotherapy of Plasmodium falciparum malaria with artesunate: Postulation of “dormancy,” a partial cytostatic effect of the drug, and its implication for treatment regimens. Parasitology, 121, 237–246.
Hoskins, J.M., Shenfield, G.M., and Gross, A.S. (1998). Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population. Br. J. Clin. Pharmacol., 46, 499–504.
Hung, T.Y., Davis, T.M., Ilett, K.F. et al. (2004). Population pharmacokinetics of piperaquine in adults and children with uncomplicated falciparum or vivax malaria. Br. J. Clin. Pharmacol., 57, 253–262.
Hyde, J.E. (1990). The dihydrofolate reductase-thymidylate synthetase gene in the drug resistance of malaria parasites. Pharmacol. Ther., 48, 45–59.
Hyde, J.E. (2002). Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect., 4, 165–174.
Ilett, K.F., Ethell, B.T., Maggs, J.L. et al. (2002). Glucuronidation of dihydroartemisinin in vivo and by human liver microsomes and expressed UDP-glucuronosyltransferases. Drug Metab. Dispos., 30, 1005–1012.
Imwong, M., Pukrittakayamee, S., Looareesuwan, S. et al. (2001). Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: Geographical and clinical correlates. Antimicrob. Agents Chemother., 45, 3122–3127.
Imwong, M., Pukrittayakamee, S., Renia, L. et al. (2003). Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: Evidence for sequential selection by drug pressure. Antimicrob. Agents Chemother., 47, 1514–1521.
Ingelman-Sundberg, M. (2001). Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy. J. Intern. Med., 250, 186–200.
Ingelman-Sundberg, M. (2004a). Human drug metabolising cytochrome P450 enzymes: Properties and polymorphisms. Naunyn Schmiedebergs. Arch. Pharmacol., 369, 89–104.
Ingelman-Sundberg, M. (2004b). Pharmacogenetics of cytochrome P450 and its applications in drug therapy: The past, present and future. Trends Pharmacol. Sci., 25, 193–200.
Inselberg, J. (1985). Induction and isolation of artemisinin-resistant mutants of Plasmodium falciparum. Am. J. Trop. Med. Hyg., 34, 417–418.
Ittarat, W., Pickard, A.L., Rattanasinganchan, P. et al. (2003). Recrudescence in artesunate-treated patients with falciparum malaria is dependent on parasite burden not on parasite factors. Am. J. Trop. Med. Hyg., 68, 147–152.
Johnson, D.J., Fidock, D.A., Mungthin, M. et al. (2004). Evidence for a central role for PfCRT in conferring Plasmodium falciparum resistance to diverse antimalarial agents. Mol, Cell, 15, 867–877.
Jung, M., Lee, K., Kim, H. et al. (2004). Recent advances in artemisinin and its derivatives as antimalarial and antitumor agents. Curr. Med. Chem., 11, 1265–1284.
Kain, K.C. (1995). Chemotherapy and prevention of drug-resistant malaria. Wilderness Environ. Med., 6, 307–324.
Kaneko, A., Bergqvist, Y., Takechi, M. et al. (1999). Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J. Infect. Dis., 179, 974–979.
Kaneko, A., Kaneko, O., Taleo, G. et al. (1997). High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet, 349, 921–922.
Karim, E.A., Ibrahim, K.E., Hassabalrasoul, M.A. et al. (1992). A study of chloroquine and desethylchloroquine plasma levels in patients infected with sensitive and resistant malaria parasites. J. Pharm. Biomed. Anal., 10, 219–223.
Karunajeewa, H., Lim, C., Hung, T.Y. et al. (2004). Safety evaluation of fixed combination piperaquine plus dihydroartemisinin (Artekin) in Cambodian children and adults with malaria. Br. J. Clin. Pharmacol., 57, 93–99.
Karunajeewa, H.A., Ilett, K.F., Dufall, K. et al. (2004). Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria. Antimicrob. Agents Chemother., 48, 2966–2972.
Kawamoto, F., Liu, Q., Ferreira, M.U. et al. (1999). How prevalent are Plasmodium ovale and P. imalariae in East Asia? Parasitol. Today, 15, 422–426.
Ketrangsee, S., Vijaykadga, S., Yamokgul, P. et al. (1992). Comparative trial on the response of Plasmodium falciparum to halofantrine and mefloquine in Trat province, eastern Thailand. Southeast Asian J. Trop. Med. Public. Health, 23, 55–58.
Kim, K.A., Park, J.Y., Lee, J.S. et al. (2003). Cytochrome P450 2C8 and CYP3A4/5 are involved in chloroquine metabolism in human liver microsomes. Arch. Pharm. Res., 26, 631–637.
Kofoed, P.E., Poulsen, A., Co, F. et al. (2003). No benefits from combining chloroquine with artesunate for 3 days for treatment of Plasmodium falciparum in Guinea-Bissau. Trans. R. Soc. Trop. Med. Hyg., 97, 429–433.
Koopmans, R., Duc, D.D., Kager, P.A. et al. (1998). The pharmacokinetics of artemisinin suppositories in Vietnamese patients with malaria. Trans. R. Soc. Trop. Med. Hyg., 92, 434–436.
Koopmans, R., Ha, L.D., Duc, D.D. et al. (1999). The pharmacokinetics of artemisinin after administration of two different suppositories to healthy Vietnamese subjects. Am. J. Trop. Med. Hyg., 60, 244–247.
Korsinczky, M., Chen, N., Kotecka, B. et al. (2000). Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drugbinding site. Antimicrob. Agents Chemother., 44, 2100–2108.
Korsinczky, M., Fischer, K., Chen, N. et al. (2004). Sulfadoxine resistance in Plasmodium vivax is associated with a specific amino acid in dihydropteroate synthase at the putative sulfadoxinebinding site. Antimicrob. Agents Chemother., 48, 2214–2222.
Krishna, S. and White, N.J. (1996). Pharmacokinetics of quinine, chloroquine and amodiaquine. Clinical implications. Clin. Pharmacokinet., 30, 263–299.
Krishna, S., Planche, T., Agbenyega, T. et al. (2001). Bioavailability and preliminary clinical efficacy of intrarectal artesunate in Ghanaian children with moderate malaria. Antimicrob. Agents Chemother., 45, 509–516.
Kumar, N. and Zheng, H. (1990). Stage-specific gametocytocidal effect in vitro of the antimalaria drug qinghaosu on Plasmodium falciparum. Parasitol. Res., 76, 214–218.
Lang, T. and Greenwood, B. (2003). The development of Lapdap, an affordable new treatment for malaria. Lancet Infect. Dis., 3, 162–168.
Laufer, M.K. and Plowe, C.V. (2004). Withdrawing antimalarial drugs: Impact on parasite resistance and implications for malaria treatment policies. Drug Resist Updat., 7, 279–288.
Le Bras, J. and Durand, R. (2003). The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum. Fundam. Clin. Pharmacol., 17, 147–153.
Le Mire, J., Arnulf, L., and Guibert, P. (2004). Malaria: control strategies, chemoprophylaxis, diagnosis, and treatment. Clin. Occup. Environ. Med., 4, 143–165.
Le, T.A., Davis, T.M., Tran, Q.B. et al. (1997). Delayed parasite clearance in a splenectomized patient with falciparum malaria who was treated with artemisinin derivatives. Clin. Infect. Dis., 25, 923–925.
Leartsakulpanich, U., Imwong, M., Pukrittayakamee, S. et al. (2002). Molecular characterization of dihydrofolate reductase in relation to antifolate resistance in Plasmodium vivax. Mol. Biochem. Parasitol., 119, 63–73.
Lee, I.S. and Hufford, C.D. (1990). Metabolism of antimalarial sesquiterpene lactones. Pharmacol. Ther., 48, 345–355.
Lefevre, G., Bindschedler, M., Ezzet, F. et al. (2000). Pharmacokinetic interaction trial between coartemether and mefloquine. Eur. J. Pharm. Sci., 10, 141–151.
Li, X.Q., Bjorkman, A., Andersson, T.B. et al. (2002). Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: A new high affinity and turnover enzymespecific probe substrate. J. Pharmacol. Exp. Ther., 300, 399–407.
Li, X.Q., Bjorkman, A., Andersson, T.B. et al. (2003). Identification of human cytochrome P(450)s that metabolise antiparasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data. Eur. J. Clin. Pharmacol., 59, 429–442.
Linder, M.W., Prough, R.A., and Valdes, R. Jr. (1997). Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin. Chem., 43, 254–266.
Little, J.M., Lester, R., Kuipers, F. et al. (1999). Variability of human hepatic UDP-glucuronosyltransferase activity. Acta Biochim. Pol., 46, 351–363.
Looareesuwan, S., Wilairatana, P., Krudsood, S. et al. (1999). Chloroquine sensitivity of Plasmodium vivax in Thailand. Ann. Trop. Med. Parasitol., 93, 225–230.
Lopes, D., Rungsihirunrat, K., Nogueira, F. et al. (2002). Molecular characterization of drug-resistant Plasmodium falciparum from Thailand. Malar. J., 1, 12.
Lowenthal, M.N. (1999). Plasmodium ovale in southern Africa. Trans. R. Soc. Trop. Med. Hyg., 93, 107.
Lu, A.H., Shu, Y., Huang, S.L. et al. (2000). In vitro proguanil activation to cycloguanil is mediated by CYP2C19 and CYP3A4 in adult Chinese liver microsomes. Acta Pharmacol. Sin., 21, 747–752.
Luxemburger, C., Brockman, A., Silamut, K. et al. (1998). Two patients with falciparum malaria and poor in vivo responses to artesunate. Trans. R. Soc. Trop. Med. Hyg., 92, 668–669.
Lysenko, A.J. and Beljaev, A.E. (1969). An analysis of the geographical distribution of Plasmodium ovale. Bull. World Health Organ., 40, 383–394.
Mackenzie, P.I., Gregory, P.A., Gardner-Stephen, D.A. et al. (2003). Regulation of UDP glucuronosyltransferase genes. Curr. Drug Metab., 4, 249–257.
Mackenzie, P.I., Miners, J.O., and McKinnon, R.A. (2000). Polymorphisms in UDP glucuronosyltransferase genes: functional consequences and clinical relevance. Clin. Chem. Lab. Med., 38, 889–892.
Mackenzie, P.I., Owens, I.S., Burchell, B. et al. (1997). The UDP glycosyltransferase gene superfamily: Recommended nomenclature update based on evolutionary divergence. Pharmacogenetics, 7, 255–269.
Maguire, J.D., Sumawinata, I.W., Masbar, S. et al. (2002). Chloroquine-resistant Plasmodium malariae in south Sumatra, Indonesia. Lancet, 360, 58–60.
Maitland, K., Bejon, P., and Newton, C.R. (2003). Malaria. Curr. Opin. Infect. Dis., 16, 389–395.
Maitland, K., Williams, T.N., Kotecka, B.M. et al. (1997). Plasma chloroquine concentrations in young and older malaria patients treated with chloroquine. Acta Trop., 66, 155–161.
Marlar-Than, Myat-Phone-Kyaw, Aye-Yu-Soe et al. (1995). Development of resistance to chloroquine by Plasmodium vivax in Myanmar. Trans. R. Soc. Trop. Med. Hyg., 89, 307–308.
Masimirembwa, C., Bertilsson, L., Johansson, I. et al. (1995). Phenotyping and genotyping of S mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin. Pharmacol. Ther., 57, 656–661.
Masimirembwa, C.M., Gustafsson, L.L., Dahl, M.L. et al. (1996). Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S-mephenytoin (CYP2C19) hydroxylation phenotypes. Br. J. Clin. Pharmacol., 41, 344–346.
Masimirembwa, C.M., Thompson, R., and Andersson, T.B. (2001). In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery. Comb. Chem. High Throughput Screen., 4, 245–263.
Masta, A., Lum, J.K., Tsukahara, T. et al. (2003). Analysis of Sepik populations of Papua New Guinea suggests an increase of CYP2C19 null allele frequencies during the colonization of Melanesia. Pharmacogenetics, 13, 697–700.
May, D.G., Porter, J., Wilkinson, G.R. et al. (1994). Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin. Pharmacol. Ther., 55, 492–500.
May, J. and Meyer, C.G. (2003). Association of Plasmodium falciparum chloroquine resistance transporter variant T76 with age-related plasma chloroquine levels. Am. J. Trop. Med. Hyg., 68, 143–146.
Mberu, E.K., Wansor, T., Sato, H. et al. (1995). Japanese poor metabolizers of proguanil do not have an increased risk of malaria chemoprophylaxis breakthrough. Trans. R. Soc. Trop. Med. Hyg., 89, 658–659.
McGready, R. and Nosten, F. (1999). The Thai-Burmese border: Drug studies of Plasmodium falciparum in pregnancy. Ann. Trop. Med. Parasitol., 93, S19–S23.
McKinnon, R.A. (2000). Cytochrome P450. 1. Multiplicity and function. Aust. J. Hosp. Pharm., 30, 54–56.
Meech, R. and Mackenzie, P.I. (1997). Structure and function of uridine diphosphate glucuronosyltransferases. Clin. Exp. Pharmacol. Physiol., 24, 907–915.
Meech, R. and Mackenzie, P.I. (1998). Determinants of UDP glucuronosyltransferase membrane association and residency in the endoplasmic reticulum. Arch. Biochem. Biophys., 356, 77–85.
Mehlotra, R.K., Lorry, K., Kastens, W. et al. (2000). Random distribution of mixed species malaria infections in Papua New Guinea. Am. J. Trop. Med. Hyg., 62, 225–231.
Mendis, K., Sina, B.J., Marchesini, P. et al. (2001). The neglected burden of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg., 64, 97–106.
Mihara, K., Svensson, U.S., Tybring, G. et al. (1999). Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19. Fundam. Clin. Pharmacol., 13, 671–675.
Miller, J.L. and Trepanier, L.A. (2002). Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. Eur. J. Clin. Pharmacol., 58, 69–72.
Miller, M.S., McCarver, D.G., Bell, D.A. et al. (1997). Genetic polymorphisms in human drug metabolic enzymes. Fundam. Appl. Toxicol., 40, 1–14.
Miners, J.O. and Birkett, D.J. (1998). Cytochrome P4502C9: An enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol., 45, 525–538.
Miners, J.O. and Mackenzie, P.I. (1991). Drug glucuronidation in humans. Pharmacol. Ther., 51, 347–369.
Miners, J.O., McKinnon, R.A., and Mackenzie, P.I. (2002). Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology, 181–182, 453–456.
Mita, T., Akira, K., Lum, J.K. et al. (2004). Expansion of wild-type allele rather than back mutation in pfcrt explains the recent recovery of chloroquine sensitivity of Plasmodium falciparum in Malawi. Mol. Biochem. Parasitol., 135, 159–163.
Mockenhaupt, F.P. (1995). Mefloquine resistance in Plasmodium falciparum. Parasitol. Today, 11, 248–253.
Mockenhaupt, F.P., May, J., Bergqvist, Y. et al. (2000). Concentrations of chloroquine and malaria parasites in blood in Nigerian children. Antimicrob. Agents Chemother., 44, 835–839.
Mohapatra, P.K., Namchoom, N.S., Prakash, A. et al. (2003). Therapeutic efficacy of antimalarials in Plasmodium falciparum malaria in an Indo-Myanmar border area of Arunachal Pradesh. Indian J. Med. Res., 118, 71–76.
Monaghan, G., Clarke, D.J., Povey, S. et al. (1994). Isolation of a human YAC contig encompassing a cluster of UGT2 genes and its regional localization to chromosome 4q13. Genomics, 23, 496–499.
Mu, J., Ferdig, M.T., Feng, X. et al. (2003). Multiple transporters associated with malaria parasite responses to chloroquine and quinine. Mol. Microbiol., 49, 977–989.
Muehlen, M., Schreiber, J., Ehrhardt, S. et al. (2004). Short communication: Prevalence of mutations associated with resistance to atovaquone and to the antifolate effect of proguanil in Plasmodium falciparum isolates from northern Ghana. Trop. Med. Int. Health, 9, 361–363.
Murphy, G.S., Basri, H., Purnomo et al. (1993). Vivax malaria resistant to treatment and prophylaxis with chloroquine. Lancet, 341, 96–100.
Nagata, K. and Yamazoe, Y. (2002). Genetic polymorphism of human cytochrome P450 involved in drug metabolism. Drug Metabol. Pharmacokin., 17, 167–189.
Nagesha, H.S., Din-Syafruddin, Casey, G.J. et al. (2001). Mutations in the pfmdr1, dhfr and dhps genes of Plasmodium falciparum are associated with in vivo drug resistance in west Papua, Indonesia. Trans. R. Soc. Trop. Med. Hyg., 95, 43–49.
Nair, S., Williams, J.T., Brockman, A. et al. (2003). A selective sweep driven by pyrimethamine treatment in southeast asian malaria parasites. Mol. Biol. Evol.. 20, 1526–1536.
Navaratnam, V., Mansor, S.M., Sit, N.W. et al. (2000). Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet., 39, 255–270.
Nelson, D.R., Zeldin, D.C., Hoffman, S.M. et al. (2004). Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics, 14, 1–18.
Nielsen, T.L., Rasmussen, B.B., Flinois, J.P. et al. (1999). In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes. J. Pharmacol. Exp. Ther., 289, 31–37.
Nomura, T., Carlton, J.M., Baird, J.K. et al. (2001). Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria. J. Infect. Dis., 183, 1653–1661.
Nosten, F. and Ashley, E. (2004). The detection and treatment of Plasmodium falciparum malaria: Time for change. J. Postgrad. Med., 50, 35–39.
Nosten, F., Hien, T.T., and White, N.J. (1998). Use of artemisinin derivatives for the control of malaria. Med. Trop. (Mars), 58, 45–49.
Nosten, F., McGready, R., Simpson, J.A. et al. (1999). Effects of Plasmodium vivax malaria in pregnancy. Lancet, 354, 546–549.
Ochong, E.O., van den Broek, IV, Keus, K. et al. (2003). Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am. J. Trop. Med. Hyg., 69, 184–187.
Oduola, A.M., Sowunmi, A., Milhous, W.K. et al. (1992). Innate resistance to new antimalarial drugs in Plasmodium falciparum from Nigeria. Trans. R. Soc. Trop. Med. Hyg., 86, 123–126.
Olliaro, P.L. and Taylor, W.R. (2004). Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: A review. J. Postgrad. Med., 50, 40–44.
Omari, A.A., Gamble, C., and Garner, P. (2004). Artemether-lumefantrine for uncomplicated malaria: A systematic review. Trop. Med. Int. Health, 9, 192–199.
O’Neill, P.M., Scheinmann, F., Stachulski, A.V. et al. (2001). Efficient preparations of the betaglucuronides of dihydroartemisinin and structural confirmation of the human glucuronide metabolite. J. Med. Chem., 44, 1467–1470.
Owens, I.S. and Ritter, J.K. (1995). Gene structure at the human UGT1 locus creates diversity in isozyme structure, substrate specificity, and regulation. Prog. Nucleic Acid Res. Mol. Biol., 51, 305–338.
Payne, D. (1987). Spread of chloroquine resistance in Plasmodium falciparum. Parasitol. Today, 3, 241–246.
Persson, I., Aklillu, E., Rodrigues, F. et al. (1996). S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics, 6, 521–526.
Peters, W. (1987). Chemotherapy and Drug Resistance in Malaria, 2nd ed. Academic, London, UK. p. 1091.
Peters, W. (1998). Drug resistance in malaria parasites of animals and man. Adv. Parasitol., 41, 1–62.
Peterson, D.S., Milhous, W.K., and Wellems, T.E. (1990). Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium falciparum malaria. Proc. Natl. Acad. Sci. USA, 87, 3018–3022.
Peterson, D.S., Walliker, D., and Wellems, T.E. (1988). Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA, 85, 9114–9118.
Pettinelli, F., Pettinelli, M.E., Eldin de Pecoulas, P. et al. (2004). Short report: High prevalence of multidrug-resistant Plasmodium falciparum malaria in the French territory of Mayotte. Am. J. Trop. Med. Hyg., 70, 635–637.
Phan, G.T., de Vries, P.J., Tran, B.Q. et al. (2002). Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam. Trop. Med. Int. Health, 7, 858–864.
Phillips, E.J., Keystone, J.S., and Kain, K.C. (1996). Failure of combined chloroquine and high-dose primaquine therapy for Plasmodium vivax malaria acquired in Guyana, South America. Clin. Infect. Dis., 23, 1171–1173.
Pickard, A.L., Wongsrichanalai, C., Purfield, A. et al. (2003). Resistance to antimalarials in Southeast Asia and genetic polymorphisms in pfmdr1. Antimicrob. Agents Chemother., 47, 2418–2423.
Plowe, C.V., Cortese, J.F., Djimde, A. et al. (1997). Mutations in Plasmodium falciparum dihydrofolate reductase and dihydropteroate synthase and epidemiologic patterns of pyrimethamine-sulfadoxine use and resistance. J. Infect. Dis., 176, 1590–1596.
Ploypradith, P. (2004). Development of artemisinin and its structurally simplified trioxane derivatives as antimalarial drugs. Acta Trop., 89, 329–342.
Price, R.N. (2000). Artemisinin drugs: novel antimalarial agents. Expert Opin. Investig. Drugs, 9, 1815–1827.
Projean, D., Baune, B., Farinotti, R. et al. (2003). In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation. Drug Metab. Dispos., 31, 748–754.
Randrianarivelojosia, M., Raharimalala, L.A., Randrianasolo, L. et al. (2001). Madagascan isolates of Plasmodium falciparum showing low sensitivity to artemether in vitro. Ann. Trop. Med. Parasitol., 95, 237–243.
Reed, M.B., Saliba, K.J., Caruana, S.R. et al. (2000). Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. Nature, 403, 906–909.
Ringwald, P., Bickii, J., and Basco, L.K. (1999). In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon. Am. J. Trop. Med. Hyg., 61, 187–192.
Ringwald, P., Same Ekobo, A., Keundjian, A. et al. (2000). Chemoresistance of P. falciparum in urban areas of Yaounde, Cameroon. Part 1: Surveillance of in vitro and in vivo resistance of Plasmodium falciparum to chloroquine from 1994 to 1999 in Yaounde, Cameroon. Trop. Med. Int. Health, 5, 612–619.
Ritter, J.K., Chen, F., Sheen, Y.Y. et al. (1992). A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem., 267, 3257–3261.
Rodrigues, A.D. (1999). Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem. Pharmacol., 57, 465–480.
Schwartz, E., Bujanover, S., and Kain, K.C. (2003). Genetic confirmation of atovaquone-proguanil-resistant Plasmodium falciparum malaria acquired by a nonimmune traveler to East Africa. Clin. Infect. Dis., 37, 450–451.
Schwartz, E., Regev-Yochay, G., and Kurnik, D. (2000). Short report: A consideration of primaquine dose adjustment for radical cure of Plasmodium vivax malaria. Am. J. Trop. Med. Hyg., 62, 393–395.
Scopel, K.K., Fontes, C.J., Nunes, A.C. et al. (2004). High prevalence of Plamodium malariae infections in a Brazilian Amazon endemic area (Apiacas-Mato Grosso State) as detected by polymerase chain reaction. Acta Trop., 90, 61–64.
Sen, S. and Ferdig, M. (2004). QTL analysis for discovery of genes involved in drug responses. Curr. Drug Targets Infect. Disord., 4, 53–63.
Shmuklarsky, M.J., Klayman, D.L., Milhous, W.K. et al. (1993). Comparison of beta-artemether and beta-arteether against malaria parasites in vitro and in vivo. Am. J. Trop. Med. Hyg., 48, 377–384.
Sibley, C.H., Hyde, J.E., Sims, P.F. et al. (2001). Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum: What next? Trends Parasitol., 17, 582–588.
Sidhu, A.B., Verdier-Pinard, D., and Fidock, D.A. (2002). Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations. Science, 298, 210–213.
Simonsson, U.S., Jansson, B., Hai, T.N. et al. (2003). Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin. Pharmacol. Ther., 74, 32–43.
Simooya, O.O., Sijumbil, G., Lennard, M.S. et al. (1998). Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians. Br. J. Clin. Pharmacol., 45, 315–317.
Sims, P., Wang, P., and Hyde, J.E. (1999). Selection and synergy in Plasmodium falciparum. Parasitol. Today, 15, 132–134.
Singh, B., Kim Sung, L., Matusop. A. et al. (2004). A large focus of naturally acquired Plasmodium knowlesi infections in human beings. Lancet, 363, 1017–1024.
Sirima, S.B., Tiono, A.B., Konate, A. et al. (2003). Efficacy of artesunate plus chloroquine for the treatment of uncomplicated malaria in children in Burkina Faso: A double-blind, randomized, controlled trial. Trans. R. Soc. Trop. Med. Hyg., 97, 345–349.
Skjelbo, E., Mutabingwa, T.K., Bygbjerg, I. et al. (1996). Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians. Clin. Pharmacol. Ther., 59, 304–311.
Smoak, B.L., DeFraites, R.F., Magill, A.J. et al. (1997). Plasmodium vivax infections in U.S. Army troops: Failure of primaquine to prevent relapse in studies from Somalia. Am. J. Trop. Med. Hyg., 56, 231–234.
Snewin, V.A., England, S.M., Sims, P.F. et al. (1989). Characterisation of the dihydrofolate reductase-thymidylate synthetase gene from human malaria parasites highly resistant to pyrimethamine. Gene, 76, 41–52.
Snow, R.W., Trape, J.F., and Marsh, K. (2001). The past, present and future of childhood malaria mortality in Africa. Trends Parasitol., 17, 593–597.
Somogyi, A.A., Reinhard, H.A., and Bochner, F. (1996). Pharmacokinetic evaluation of proguanil: A probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br. J. Clin. Pharmacol., 41, 175–179.
Soto, J., Toledo, J., Gutierrez, P. et al. (2001). Plasmodium vivax clinically resistant to chloroquine in Colombia. Am. J. Trop. Med. Hyg., 65, 90–93.
Srivastava, I.K. and Vaidya, A.B. (1999). A mechanism for the synergistic antimalarial action of atovaquone and proguanil. Antimicrob. Agents Chemother, 43, 1334–1339.
Steketee, R.W., Nahlen, B.L., Parise, M.E. et al. (2001). The burden of malaria in pregnancy in malaria-endemic areas. Am. J. Trop. Med. Hyg., 64, 28–35.
Stormer, E., von Moltke, L.L., and Greenblatt, D.J. (2000). Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: A comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J. Pharmacol. Exp. Ther., 295, 793–801.
Suh, K.N., Kain, K.C., and Keystone, J.S. (2004). Malaria. CMAJ. 170, 1693–1702.
Svensson, U.S. and Ashton, M. (1999). Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin. Br. J. Clin. Pharmacol., 48, 528–535.
Svensson, U.S., Ashton, M., Trinh, N.H. et al. (1998). Artemisinin induces omeprazole metabolism in human beings. Clin. Pharmacol. Ther., 64, 160–167.
Tahar, R., Ringwald, P., and Basco, L.K. (1998). Heterogeneity in the circumsporozoite protein gene of Plasmodium malariae isolates from subSaharan Africa. Mol. Biochem. Parasitol., 92, 71–78.
Talisuna, A.O., Bloland, P., and D’Alessandro, U. (2004). History, dynamics, and public health importance of malaria parasite resistance. Clin. Microbiol. Rev., 17, 235–254.
Taylor, W.R. and White, N.J. (2004). Antimalarial drug toxicity: A review. Drug Saf., 27, 25–61.
ter Kuile, F., White, N.J., Holloway, P. et al. (1993). Plasmodium falciparum: In vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria. Exp. Parasitol., 76, 85–95.
ter Kuile, F.O., Dolan, G., Nosten, F. et al. (1993). Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet, 341, 1044–1049.
Thapar, M.M., Ashton, M., Lindegardh, N. et al. (2002). Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis. Eur. J. Clin. Pharmacol., 58, 19–27.
Tobian, A.A., Mehlotra, R.K., Malhotra, I. et al. (2000). Frequent umbilical cord-blood and maternal-blood infections with Plasmodium falciparum, P. malariae, and P. ovale in Kenya. J. Infect. Dis., 182, 558–563.
Tran, T.H., Dolecek, C., Pham, P.M. et al. (2004). Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomized clinical trial. Lancet, 363, 18–22.
Tredger, J.M. and Stoll, S. (2002). Cytochrome P450 their impact on drug treatment. Hospital Pharmacy, 9, 167–173.
Treeprasertsuk, S., Viriyavejakul, P., Silachamroon, U. et al. (2000). Is there any artemisinin resistance in falciparum malaria? Southeast Asian J. Trop. Med. Public Health, 31, 825–828.
Triglia, T. and Cowman, A.F. (1994). Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum. Proc. Natl. Acad. Sci. USA., 91, 7149–7153.
Triglia, T., Menting, J.G., Wilson, C. et al. (1997). Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in Plasmodium falciparum. Proc. Natl. Acad. Sci. USA, 94, 13,944–13,949.
Triglia, T., Wang, P., Sims, P.F. et al. (1998). Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. EMBO. J., 17, 3807–3815.
Turgeon, D., Carrier, J.S., Levesque, E. et al. (2000). Isolation and characterization of the human UGT2B15 gene, localized within a cluster of UGT2B genes and pseudogenes on chromosome 4. J. Mol. Biol., 295, 489–504.
Ukpe, I.S. (1998). Plasmodium ovale in South Africa. Trans. R. Soc. Trop. Med. Hyg., 92, 574.
van Agtmael, M.A., Gupta, V., van der Graaf, C.A., and van Boxtel, C.J. (1999a). The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin. Pharmacol. Ther., 66, 408–414.
van Agtmael, M.A., Gupta, V., van der Wosten, T.H. et al. (1999b). Grapefruit juice increases the bioavailability of artemether. Eur. J. Clin. Pharmacol., 55, 405–410.
van Agtmael, M.A., Van Der Graaf, C.A., Dien, T.K. et al. (1998). The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects. Eur. J. Drug Metab. Pharmacokinet., 23, 429–436.
Vieira, P.P., Ferreira, M.U., Das Gracas Alecrim, M. et al. (2004). pfcrt Polymorphism and the Spread of Chloroquine Resistance in Plasmodium falciparum Populations across the Amazon Basin. J. Infect. Dis., 190, 417–424.
Volkman, S. and Wirth, D. (1998). Functional analysis of pfmdr1 gene of Plasmodium falciparum. Methods Enzymol., 292, 174–181.
Walker, O., Dawodu, A.H., Adeyokunnu, A.A. et al. (1983). Plasma chloroquine and desethylchloroquine concentrations in children during and after chloroquine treatment for malaria. Br. J. Clin. Pharmacol., 16, 701–705.
Wang, P., Lee, C.S., Bayoumi, R. et al. (1997). Resistance to antifolates in Plasmodium falciparum monitored by sequence analysis of dihydropteroate synthetase and dihydrofolate reductase alleles in a large number of field samples of diverse origins. Mol. Biochem. Parasitol., 89, 161–177.
Wang, P., Read, M., Sims, P.F. et al. (1997). Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Mol. Microbiol., 23, 979–986.
Wang, P., Wang, Q., Aspinall, T.V. et al. (2004). Transfection studies to explore essential folate metabolism and antifolate drug synergy in the human malaria parasite Plasmodium falciparum. Mol. Microbiol., 51, 1425–1438.
Wanwimolruk, S., Bhawan, S., Coville, P.F. et al. (1998). Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. Eur. J. Clin. Pharmacol., 54, 431–435.
Wanwimolruk, S., Pratt, E.L., Denton, J.R. et al. (1995). Evidence for the polymorphic oxidation of debrisoquine and proguanil in a New Zealand Maori population. Pharmacogenetics, 5, 193–198.
Wanwimolruk, S., Wong, S.M., Zhang, H. et al. (1995). Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment. J. Pharm. Pharmacol., 47, 957–963.
Ward, S.A., Helsby, N.A., Skjelbo, E. et al. (1991). The activation of the biguanide antimalarial proguanil cosegregates with the mephenytoin oxidation polymorphism—a panel study. Br. J. Clin. Pharmacol., 31, 689–692.
Watkins, W.M., Mberu, E.K., Nevill, C.G. et al. (1990). Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans. R. Soc. Trop. Med. Hyg., 84, 492–495.
Weinshilboum, R. (2003). Inheritance and drug response. N. Engl. J. Med., 348, 529–537.
Wellems, T.E. and Plowe, C.V. (2001). Chloroquine-resistant malaria. J. Infect. Dis., 184, 770–776.
Wellems, T.E., Walker-Jonah, A., and Panton, L.J. (1991). Genetic mapping of the chloroquine-resistance locus on Plasmodium falciparum chromosome 7. Proc. Natl. Acad. Sci. US., 88, 3382–3386.
Wells, P.G., Mackenzie, P.I., Chowdhury, J.R. et al. (2004). Glucuronidation and the UDP-glucuronosyltransferases in health and disease. Drug. Metab. Dispos., 32, 281–290.
Wen, X., Wang, J.S., Backman, J.T. et al. (2002). Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab. Dispos., 30, 631–635.
Wernsdorfer, W.H. (1992). The biological and epidemiological basis of drug resistance in malaria parasites. Southeast Asian J. Trop. Med. Public Health, 23, 123–129.
Wernsdorfer, W.H. and Noedl, H. (2003). Molecular markers for drug resistance in malaria: Use in treatment, diagnosis and epidemiology. Curr. Opin. Infect. Dis., 16, 553–558.
Wernsdorfer, W.H. (1994). Epidemiology of drug resistance in malaria. Acta Trop., 56, 143–156.
Wernsdorfer, W.H. and Payne, D. (1991). The dynamics of drug resistance in Plasmodium falciparum. Pharmacol. Ther., 50, 95–121.
White, N.J. (1994). Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. Trans. R. Soc. Trop. Med. Hyg., 88, S41–43.
White, N.J. (1999). Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia, 41, 301–308.
White, N.J. (2003). Malaria. In: G.C. Cook and A. Zumla (eds), Manson’s Tropical Diseases, 21st ed. W.B. Saunders. pp. 1205–1295.[j15]
White, N.J. (2004). Antimalarial drug resistance. J. Clin. Invest., 113, 1084–1092.
White, N.J. and Olliaro, P. (1998). Artemisinin and derivatives in the treatment of uncomplicated malaria. Med. Trop. (Mars), 58, 54–56.
Wichmann, O., Betschart, B., Loscher, T. et al. (2003). Prophylaxis failure due to probable mefloquine resistant P. falciparum from Tanzania. Acta. Trop., 86, 63–65.
Wichmann, O., Jelinek, T., Peyerl-Hoffmann, G. et al. (2003). Molecular surveillance of the antifolate-resistant mutation I164L in imported African isolates of Plasmodium falciparum in Europe: Sentinel data from TropNetEurop. Malar. J., 2, 17.
Wichmann, O., Muehlen, M., Gruss, H. et al. (2004). Malarone treatment failure not associated with previously described mutations in the cytochrome b gene. Malar. J. 3, 14.
Wilairatana, P., Silachamroon, U., Krudsood, S. et al. (1999). Efficacy of primaquine regimens for primaquine-resistant Plasmodium vivax malaria in Thailand. Am. J. Trop. Med. Hyg., 61, 973–977.
Wilson, C.M., Volkman, S.K., Thaithong, S. et al. (1993). Amplification of pfmdr1 associated with mefloquine and halofantrine resistance in Plasmodium falciparum from Thailand. Mol. Biochem. Parasitol., 57, 151–160.
Win, T.T., Lin, K., Mizuno, S. et al. (2002). Wide distribution of Plasmodium ovale in Myanmar. Trop. Med. Int. Health, 7, 231–239.
Winstanley, P (2001). Chlorproguanil-dapsone (LAPDAP) for uncomplicated falciparum malaria. Trop. Med. Int. Health, 6, 952–954.
Winstanley, P.A. (2000). Chemotherapy for falciparum malaria: The armoury, the problems, and the prospects. Parasitol. Today, 16, 146–153.
Winstanley, P.A. and Watkins, W.M. (1992). Pharmacology and parasitology: Integrating experimental methods and approaches to falciparum malaria. Br. J. Clin. Pharmacol., 33, 575–581.
Winstanley, P.A., Ward, S.A., and Snow, R.W. (2002). Clinical status and implications of antimalarial drug resistance. Microbes Infect., 4, 157–164.
Winter, H.R., Wang, Y., and Unadkat, J.D. (2000). CYP2C8/9 mediate dapsone N-hydroxylation at clinical concentrations of dapsone. Drug Metab. Dispos., 28, 865–868.
Wongsrichanalai, C., Nguyen, T.D., Trieu, N.T. et al. (1997). In vitro susceptibility of Plasmodium falciparum isolates in Vietnam to artemisinin derivatives and other antimalarials. Acta Trop., 63, 151–158.
Wongsrichanalai, C., Pickard, A.L., Wernsdorfer, W.H. et al. (2002). Epidemiology of drug-resistant malaria. Lancet Infect. Dis., 2, 209–218.
Wrighton, S.A., Brian, W.R., Sari, M.A. et al. (1990). Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol. Pharmacol., 38, 207–213.
Wu, Y., Kirkman, L.A., and Wellems, T.E. (1996). Transformation of Plasmodium falciparum malaria parasites by homologous integration of plasmids that confer resistance to pyrimethamine. Proc. Natl. Acad. Sci. USA., 93, 1130–1134.
Yang, H., Liu, D., Yang, Y. et al. (2003). Changes in susceptibility of Plasmodium falciparum to artesunate in vitro in Yunnan Province, China. Trans. R. Soc. Trop. Med. Hyg., 97, 226–228.
Yusuf, I., Djojosubroto, M.W., Ikawati, R. et al. (2003). Ethnic and geographical distributions of CYP2C19 alleles in the populations of Southeast Asia. Adv. Exp. Med. Biol., 531, 37–46.
Yuthavong, Y. (2002). Basis for antifolate action and resistance in malaria. Microbes Infect., 4, 175–182.
Zhang, H., Coville, P.F., Walker, R.J. et al. (1997). Evidence for involvement of human CYP3A in the 3-hydroxylation of quinine. Br. J. Clin. Pharmacol., 43, 245–252.
Zhang, S.Q., Hai, T.N., Ilett, K.F. et al. (2001). Multiple dose study of interactions between artesunate and artemisinin in healthy volunteers. Br. J. Clin. Pharmacol., 52, 377–385.
Zhao, X.J., Yokoyama, H., Chiba, K. et al. (1996). Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450. J. Pharmacol. Exp. Ther., 279, 1327–1334.
Zolg, J.W., Plitt, J.R., Chen, G.X. et al. (1989). Point mutations in the dihydrofolate reductase-thymidylate synthase gene as the molecular basis for pyrimethamine resistance in Plasmodium falciparum. Mol. Biochem. Parasitol., 36, 253–262.
Zuidema, J., Hilbers-Modderman, E.S., and Merkus, F.W. (1986). Clinical pharmacokinetics of dapsone. Clin. Pharmacokinet., 11, 299–315.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Mehlotra, R.K., Zimmerman, P.A. (2006). Resistance to Antimalarial Drugs: Parasite and Host Genetic Factors. In: Malaria: Genetic and Evolutionary Aspects. Emerging Infectious Diseases of the 21st Century. Springer, Boston, MA. https://doi.org/10.1007/0-387-28295-5_5
Download citation
DOI: https://doi.org/10.1007/0-387-28295-5_5
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-28294-7
Online ISBN: 978-0-387-28295-4
eBook Packages: MedicineMedicine (R0)